NEW YORK ( TheStreet) -- Medicines (Nasdaq: MDCO) hit a new 52-week high Monday as it is currently trading at $19.47, above its previous 52-week high of $19.46 with 325,860 shares traded as of 3:40 p.m. ET. Average volume has been 550,000 shares over the past 30 days.

Medicines has a market cap of $1 billion and is part of the health care sector and drugs industry. Shares are up 36% year to date as of the close of trading on Friday.

The Medicines Company, a global pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. The company has a P/E ratio of 7.6, above the average drugs industry P/E ratio of six and below the S&P 500 P/E ratio of 17.7.
  • Practice your MDCO trading strategies and win cash in our stock game.

TheStreet Ratings rates Medicines as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Medicines Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

AveXis, Esperion and Amgen Among Biotech Movers